Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01811576 | Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency | PHASE2 | COMPLETED | 52 | — | — | Mar 31, 2013 | Aug 5, 2013 | Dec 10, 2021 | 23 | United States, Czechia +7 |
| Arm | Type | Description |
|---|---|---|
| recombinant human growth hormone | ACTIVE_COMPARATOR | Daily subcutaneous dose |
| TV-1106 | EXPERIMENTAL | Titration dose levels of TV-1106 |
| Name | Type | Description |
|---|---|---|
| TV-1106 | DRUG | - |
| Recombinant human growth hormone | DRUG | Subcutaneous once daily |
Inclusion Criteria: * Patient agrees to provide written informed consent and to comply with the study protocol after reading the informed consent and discussing the study with the investigator. * Males and females between 23 and 65 years of age must have a confirmed diagnosis of adult GHD, either a...